Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor in advanced thymic epithelial tumor
NCT03193437Phase 2Terminated
- Sponsor
- Georgetown University
- Start
- Apr 2018
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of selinexor in thymic epithelial tumor (TET) (2 arms), sponsored by Georgetown University. Primary endpoint: Overall Response Rate at 24 months. Started Apr 2018; status: terminated.
02
Drugs
selinexor
03
Conditions
thymic epithelial tumor (TET)
Beyond the preview
Go deeper on NCT03193437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03193437.